Israel Englander’s Encompass Health EHC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-300,000
Closed -$29M 5991
2026
Q1
$29M Buy
+300,000
New +$30.8M 0.01% 1261
2024
Q3
Sell
-20,000
Closed -$1.72M 6179
2024
Q2
$1.72M Sell
20,000
-190,000
-90% -$15.9M ﹤0.01% 3664
2024
Q1
$17.3M Buy
+210,000
New +$15.4M 0.01% 1676
2023
Q2
Sell
-403,400
Closed -$21.8M 6221
2023
Q1
$21.8M Buy
+403,400
New +$23.5M 0.01% 1275
2022
Q4
Sell
-100,000
Closed -$4.52M 6670
2022
Q3
$4.52M Buy
+100,000
New +$5M ﹤0.01% 2990
2020
Q4
Sell
-163,913
Closed -$8.47K 5278
2020
Q3
$8.47K Buy
+163,913
New +$8.41M 0.01% 1397
2020
Q2
Sell
-62,850
Closed -$3.2M 4253
2020
Q1
$3.2M Buy
+62,850
New +$3.62M 0.01% 1682
2019
Q2
Sell
-50,280
Closed -$2.34M 4137
2019
Q1
$2.34M Buy
+50,280
New +$2.55M ﹤0.01% 2314
2017
Q4
Sell
-62,850
Closed -$2.32M 3849
2017
Q3
$2.32M Buy
+62,850
New +$2.24M ﹤0.01% 2097

Other funds holding EHC

Israel Englander's EHC Position: Q2 2026 in Review

Israel Englander increased its Encompass Health (EHC) stake by 69% in Q2 2026, buying an estimated $34M and bringing the position to 805,717 shares worth $81.4M. The position accounts for 0.03% of the portfolio, ranked #615.

Israel Englander first reported a position in EHC in Q2 2013 and has held it in 48 quarters since. The position peaked at $155M in Q3 2025. 594 funds tracked by Wall St. Rank hold EHC as of Q2 2026.

  • Israel Englander held 805,717 shares of Encompass Health worth $81.4M as of Q2 2026.
  • Israel Englander bought 327,898 Encompass Health shares in Q2 2026, an estimated $34M.
  • Encompass Health made up 0.03% of Israel Englander's portfolio in Q2 2026, its #615 holding.
  • Israel Englander first reported a position in Encompass Health in Q2 2013 and has held it in 48 quarters since.
  • Israel Englander's Encompass Health position peaked at $155M in Q3 2025.
  • 594 funds tracked by Wall St. Rank held Encompass Health as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.